氰基丙烯酸酯胶所致静脉内血栓的自然病程及抗凝治疗的作用
回顾性分析2020年1月至2021年12月4321例氰基丙烯酸酯胶静脉消融术,133例(3.1%)发生静脉内胶所致血栓(EGIT)。血栓多数无延伸或迁移,趋向消退或回缩;EGIT 1和2级中86%和60%仅观察约4周即消退;抗凝/抗血小板治疗与未治疗相比对血栓消退无影响。
要点
- EGIT总发生率3.1%,其中1级57例、2级35例、3级19例、4级22例。
- 1级和2级EGIT分别有86%和60%仅观察约4周消退,抗凝/抗血小板无影响。
- 3级EGIT中68%消退或回缩,与抗凝/抗血小板使用无关。
核心结论
- 无论EGIT分级或严重程度,多数EGIT不伴血栓延伸或迁移,趋向消退或回缩。
- 对于EGIT 1级和2级患者,抗凝或抗血小板治疗不必要,因分别有86%和60%经观察约4周消退。
- 对于EGIT 3级,68%消退或回缩,与是否使用抗凝或抗血小板无关。
- EGIT 4级多数为远程小腿静脉DVT,与隐股/隐腘交界相关的EGIT 3级和4级罕见。
研究设计与样本
- 回顾性综述,纳入2020年1月至2021年12月Center for Vein Restoration所有使用氰基丙烯酸酯胶的静脉消融术。
- 共2374例患者接受4321次氰基丙烯酸酯胶手术,分为发生EGIT组(EGIT/CAG)和未发生EGIT组(CAG)。
- 分析人口学、病史、修订版静脉临床严重程度评分(rVCSS)、慢性静脉功能不全生活质量问卷(CIVIQ)、CEAP、EGIT分类、抗凝类型、消退时间、DVT位置、导管尖端距离、治疗长度和近端大腿直径。
- EGIT分类:1级为血栓延伸至深静脉且覆盖管腔面积小于25%;2级为25%至49%;3级为50%至74%;4级为完全闭塞。
主要发现
- 研究期间2374例患者接受4321次CAG手术,133例(3.1%)发生EGIT:1级57例、2级35例、3级19例、4级22例。
- 所有EGIT均通过监测扫描发现,无患者出现提示VTE的肢体或肺部症状。
- 整个队列平均年龄65.3±14.2岁,rVCSS 8.2±2.8,CIVIQ 20为48±18.3,女性89例、男性44例。
- EGIT 1级:57例中56例(98%)在4.2±5.1周消退,1例失访;抗凝/抗血小板方案包括2例阿司匹林、1例Eliquis、5例Xarelto,49例(86%)未用药。
- EGIT 2级:35例中27例(77%)在4.4±3.4周消退,1例未消退,6例回缩至1级,1例末次随访仍为2级;抗凝/抗血小板方案包括7例阿司匹林、3例Eliquis、3例Xarelto、1例Coumarin,21例(60%)未用药。
关键数值与推荐
- EGIT 1级:血栓延伸至深静脉且覆盖管腔面积小于25%。
- EGIT 2级:血栓覆盖管腔面积25%至49%。
- EGIT 3级:血栓覆盖管腔面积50%至74%。
- EGIT 4级:完全闭塞。
临床怎么用
- 本研究中心的做法是术后3至7天内进行 duplex 超声扫描以评估干预后DVT。
- 作者认为对于EGIT 1级和2级患者,抗凝或抗血小板治疗不必要,因分别有86%和60%经观察约4周消退。
- 作者认为对于EGIT 3级,68%消退或回缩,与是否使用抗凝或抗血小板无关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The natural history of endovenous glue-induced thrombus (EGIT) resolution and the role of anticoagulation (AC) and/or anti-platelet (AP) agents in their management is currently ill-defined. The goal of this investigation is to determine the clinical behavior of EGITs and whether or not AC or AP affects treatment outcomes. METHODS: We performed a retrospective review of all endovenous ablations utilizing cyanoacrylate glue (CAG) from January 2020 to December 2021 at the Center for Vein Restoration. Patients were divided into two groups: (1) patients who developed an EGIT (EGIT/CAG) and (2) patients treated with CAG and no EGIT development (CAG). Demographics, medical/surgical histories, revised Venous Clinical Severity Score (rVCSS), Chronic Venous Insufficiency Quality of Life Questionnaire (CIVIQ), CEAP, EGIT category, type of anticoagulation, resolution time, location of any deep vein thrombosis (DVT) were analyzed, catheter tip distance, treatment length and proximal thigh diameters were all analyzed. EGITs were categorized as follows: EGIT 1: thrombus extension into the deep vein covering less than 25% of the luminal area; EGIT 2: thrombus between 25% and 49%; EGIT 3: thrombus between 50% and 74%; and EGIT 4: total occlusion. Our protocol is to perform post-procedure duplex scans within 3 to 7 days after endovenous ablations to assess for post-intervention DVTs. RESULTS: During the study period, 2374 patients received 4321 CAG procedures. EGITs were observed in 133 patients (3.1%): EGIT 1 (n = 57); EGIT 2 (n = 35); EGIT 3 (n = 19); and EGIT 4 (n = 22). All EGITs were identified by surveillance scanning. No patient presented with limb or pulmonary symptoms suggestive of VTE. The average age, rVCSS, and CIVIQ 20 of the entire cohort was 65.3 ± 14.2 years, 8.2 ± 2.8, and 48 ± 18.3, respectively with 89 females and 44 males. For EGIT 1, 56 of 57 (98%) resolved at 4.2 ± 5.1 weeks, with one patient lost to follow-up. AC/AP regimen included two aspirin (ASA), one Eliquis, 5 Xarelto, and nothing in 49 patients (86%). For EGIT 2, 27 of 35 (77%) resolved at 4.4 ± 3.4 weeks, one was unresolved, six regressed to EGIT 1, and one remained an EGIT 2 at the last follow-up examination. AC/AP regimens included seven ASA, three Eliquis, three Xarelto, one Coumadin, and nothing in 21 patients (60%). For EGIT 3, 12 were in the common femoral vein (CFV), three in the popliteal vein (POPV), one in the external iliac vein, and three in the gastrocnemius veins. Nine of nineteen (47%) resolved at 6 ± 5.9 weeks, four regressed, one migrated to the proximal CFV, three became chronic, and two were lost to follow-up. AC/AP regimens included three ASA, three Eliquis, seven Xarelto, and nothing in six patients (32%). AC/AP compared with no AC/AP had no effect on clot resolution (P = .3). Of the 22 EGIT 4, one was in the CFV, two were in the POPV, and 18 (82%) were remote calf vein DVTs (15 gastrocnemius, one peroneal [PV], and three posterior tibial veins [PTVs]). The CFV EGIT became chronic, one POPV resolved, and one was lost to follow-up. For the gastrocnemius clots, five became chronic, eight resolved, and two were lost to follow-up. For the PTV clots, one resolved, one became chronic, and one was lost to follow-up. The PV clot became chronic. AC/AP regimen included four ASA, five Eliquis, six Xarelto, and nothing in seven patients. AC/AP compared with no AC/AP had no effect on clot resolution (P = .9). The average proximal thigh diameter (millimeters, mm), vein length treated (mm), and catheter distance (mm) from the junction were the following: EGIT 1 (5.9 ± 2.4, 37.5 ± 17.6, and 5.2 ± 1), EGIT 2 (5.9 ± 1.7, 38 ± 16.9, 4.79 ± 0.71), EGIT 3 (5.1 ± 2.6, 27.9 ± 16.6, and 5.26 ± 1.4), and EGIT 4 (5 ± 1.7, 29.9 ± 15.8, and 5.39 ± 2.18), respectively. Treatment length alone was significantly shorter in EGIT 3 and 4, compared with EGIT 1 and 2 (P ≤ .05). Catheter distance from the junction was longer in EGIT 1, 3, and 4 patients compared with CAG patients (P ≤ .02). CONCLUSIONS: Regardless of EGIT class or severity, the majority of EGITs are not associated with clot extension or migration and tend to resolve or regress. For EGIT class 1 and 2 patients, AC or AP therapy is not necessary, as 86% and 60%, respectively, resolved with observation alone by 4 weeks. For EGIT 3, 68% resolved or regressed regardless of AC or AP use. The majority of EGIT 4 were remote calf vein DVTs. EGIT 3 and 4 associated with the saphenofemoral/popliteal junction are rare. When compared with CAG patients, proximal thigh diameters and treatment lengths were larger and longer in EGIT 1 and 2 patients. Catheter proximity to the junction was not associated with a higher incidence of EGIT formation.
引用
- Pappas JN, Pappas PJ, Lakhanpal S, et al. Natural history and role of anticoagulation in the management of endovenous glue-induced thrombus. J Vasc Surg Venous Lymphat Disord. 2023. PMID: 37353153. doi:10.1016/j.jvsv.2023.03.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。